Premium
Sensitivity of cultured human pancreatic carcinoma cells to dihydroxyanthracenedione
Author(s) -
Fountzilas George,
Gratzner Howard,
Lim Lori O.,
Yunis Adel A.
Publication year - 1984
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910330311
Subject(s) - mitomycin c , vindesine , bleomycin , in vitro , cell culture , vinblastine , pharmacology , cell growth , biology , medicine , vincristine , chemotherapy , biochemistry , genetics , cyclophosphamide
We tested the effectiveness of dihydroxyanthracenedione (DHAD) on cell growth of two human pancreatic carcinoma cell lines MlA PaCa‐2 and PANC‐1. At the level of ID 50 , the drug was almost equally effective against both cell lines. When the time exposure of MIA PaCa‐2 cells to the drug was increased from 1 h to continuous exposure for 5 days, the ID 50 was decreased about three‐fold only (1.4 × 10 −8 M and 4 × 10 −9 M respectively). At the level of ID 50 also the difference between 6 h exposure and continuous exposure for 5 days was minimal. In equimolar concentrations and with 1 h exposure, DHAD was more effective against MIA PaCa‐2 cells than other chemotherapeutic agents including adriamycin, mitomycin‐C, 5‐FU, vincristine, vindesine, vinblastine, VP‐16–213, bleomycin, cis‐platinum, asparaginase and acivicin. In concentrations of 5 × 10 −7 M, DHAD caused about 40% inhibition of 14 C‐thymidine incorporation of MIA PaCa‐2 cells. Treatment of MIA PaCa‐2 cells with the ID 50 of DHAD for 1 h caused retardation of cellular traverse, with the major effect appearing to be in G 2 +M phase of the cycle. From these data DHAD appears to be a potent drug against human pancreatic carcinoma in vitro .